Xue W, Fulco C, Sha S, Alden N, Panteli J, Hossler P
Mol Ther Methods Clin Dev. 2024; 32(2):101266.
PMID: 38868441
PMC: 11166877.
DOI: 10.1016/j.omtm.2024.101266.
Wang J, Gessler D, Zhan W, Gallagher T, Gao G
Signal Transduct Target Ther. 2024; 9(1):78.
PMID: 38565561
PMC: 10987683.
DOI: 10.1038/s41392-024-01780-w.
Merten O
Microorganisms. 2024; 12(2).
PMID: 38399788
PMC: 10892526.
DOI: 10.3390/microorganisms12020384.
Nagy A, Chakrabarti L, Kurasawa J, Mulagapati S, Devine P, Therres J
Sci Rep. 2023; 13(1):19210.
PMID: 37932360
PMC: 10628118.
DOI: 10.1038/s41598-023-46298-3.
Jalsic L, Lytvyn V, Elahi S, Hrapovic S, Nassoury N, Chahal P
Mol Ther Methods Clin Dev. 2023; 30:259-275.
PMID: 37560197
PMC: 10407821.
DOI: 10.1016/j.omtm.2023.07.002.
AAV genome modification for efficient AAV production.
Asaad W, Volos P, Maksimov D, Khavina E, Deviatkin A, Mityaeva O
Heliyon. 2023; 9(4):e15071.
PMID: 37095911
PMC: 10121408.
DOI: 10.1016/j.heliyon.2023.e15071.
Construction of an rAAV Producer Cell Line through Synthetic Biology.
Lee Z, Lu M, Irfanullah E, Soukup M, Hu W
ACS Synth Biol. 2022; 11(10):3285-3295.
PMID: 36219557
PMC: 9595119.
DOI: 10.1021/acssynbio.2c00207.
AAV vectors: The Rubik's cube of human gene therapy.
Pupo A, Fernandez A, Low S, Francois A, Suarez-Amaran L, Samulski R
Mol Ther. 2022; 30(12):3515-3541.
PMID: 36203359
PMC: 9734031.
DOI: 10.1016/j.ymthe.2022.09.015.
Characteristics of BAY 2599023 in the Current Treatment Landscape of Hemophilia A Gene Therapy.
Pipe S, Arruda V, Lange C, Kitchen S, Eichler H, Wadsworth S
Curr Gene Ther. 2022; 23(2):81-95.
PMID: 36111754
PMC: 10186383.
DOI: 10.2174/1566523222666220914105729.
Viral vector platforms within the gene therapy landscape.
Bulcha J, Wang Y, Ma H, Tai P, Gao G
Signal Transduct Target Ther. 2021; 6(1):53.
PMID: 33558455
PMC: 7868676.
DOI: 10.1038/s41392-021-00487-6.
Repeat Dosing of AAV2.5T to Ferret Lungs Elicits an Antibody Response That Diminishes Transduction in an Age-Dependent Manner.
Tang Y, Yan Z, Lin S, Huntemann E, Feng Z, Park S
Mol Ther Methods Clin Dev. 2020; 19:186-200.
PMID: 33209961
PMC: 7648090.
DOI: 10.1016/j.omtm.2020.09.008.
Secreted TRAIL gene-modified adipose-derived stem cells exhibited potent tumor-suppressive effect in hepatocellular carcinoma cells.
Liu Z, Li S, Ma T, Zeng J, Zhou X, Li H
Immun Inflamm Dis. 2020; 9(1):144-156.
PMID: 33156578
PMC: 7860607.
DOI: 10.1002/iid3.372.
MicroRNA-based recombinant AAV vector assembly improves efficiency of suicide gene transfer in a murine model of lymphoma.
Khan N, Cheemadan S, Saxena H, Bammidi S, Jayandharan G
Cancer Med. 2020; 9(9):3188-3201.
PMID: 32108448
PMC: 7196056.
DOI: 10.1002/cam4.2935.
Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?.
Keeler A, Flotte T
Annu Rev Virol. 2019; 6(1):601-621.
PMID: 31283441
PMC: 7123914.
DOI: 10.1146/annurev-virology-092818-015530.
Adeno-associated virus vector as a platform for gene therapy delivery.
Wang D, Tai P, Gao G
Nat Rev Drug Discov. 2019; 18(5):358-378.
PMID: 30710128
PMC: 6927556.
DOI: 10.1038/s41573-019-0012-9.
Accurate Titration of Infectious AAV Particles Requires Measurement of Biologically Active Vector Genomes and Suitable Controls.
Francois A, Bouzelha M, Lecomte E, Broucque F, Penaud-Budloo M, Adjali O
Mol Ther Methods Clin Dev. 2018; 10:223-236.
PMID: 30112419
PMC: 6090651.
DOI: 10.1016/j.omtm.2018.07.004.
Gene therapy for neurological disorders: progress and prospects.
Deverman B, Ravina B, Bankiewicz K, Paul S, Sah D
Nat Rev Drug Discov. 2018; 17(9):641-659.
PMID: 30093643
DOI: 10.1038/nrd.2018.110.
Pharmacology of Recombinant Adeno-associated Virus Production.
Penaud-Budloo M, Francois A, Clement N, Ayuso E
Mol Ther Methods Clin Dev. 2018; 8:166-180.
PMID: 29687035
PMC: 5908265.
DOI: 10.1016/j.omtm.2018.01.002.
Molecular design for recombinant adeno-associated virus (rAAV) vector production.
Aponte-Ubillus J, Barajas D, Peltier J, Bardliving C, Shamlou P, Gold D
Appl Microbiol Biotechnol. 2017; 102(3):1045-1054.
PMID: 29204900
PMC: 5778157.
DOI: 10.1007/s00253-017-8670-1.
Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment.
Wright J
Biomedicines. 2017; 2(1):80-97.
PMID: 28548061
PMC: 5423478.
DOI: 10.3390/biomedicines2010080.